

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	620-445	Unknown
	APPLICANT	
	BERNARDS ET AL.	
(Use several sheets if necessary)	FILING DATE	TC/A.U.
	July 24, 2006	Unknown

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Partial International Search Report for PCT/EP2005/000937.
	Ikeda et al., <i>Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor</i> , <i>Immunity</i> , vol. 6, no. 2, February 1997, pp. 199-208, XP002216277.
	Plumb et al., <i>Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101</i> , <i>Molecular Cancer Therapeutics</i> , vol. 2, no. 8, August 2003, pp. 721-728, XP002372785.
	Freemantle et al., <i>Retinoids in cancer therapy and chemoprevention: Promise meets resistance</i> , <i>Oncogene</i> , vol. 22, no. 47, 20 October 2003, pp. 7305-7315, XP008061601.
	Brummelkamp et al., <i>Stable Suppression of Tumorigenicity by Virus-Mediated RNA Interference</i> , <i>Cancer Cell</i> , vol. 2, no. 3, September 2002, pp. 243-247, XP009006464.
	Epping et al., <i>The Human Tumor Antigen Prame is a Dominant Repressor of Retinoic Acid Receptor Signaling</i> , <i>Cell</i> , vol. 122, no. 6, 23 September 2004, pp. 835-847, XP008061580.
	Tajeddine et al., <i>Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo</i> , <i>Cancer Research</i> , vol. 65, no. 16, August 2005, pp. 7348-7355, XP002372786.
	Product: sc-37322, Online Catalog of Santa Cruz Biotechnology, Inc., 2004, XP002372787.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.